Jaguar Health, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Jaguar Health, Inc. reported a net comprehensive loss of $54.4 million for 2025, an increase from $39.0 million in 2024, while securing $18 million in upfront non-dilutive capital from a US licensing agreement for Mytesi and Canalevia-CA1.
NASDAQ
10-K/A: Jaguar Health Files Amendment to 10-K, Discloses Executive and Director Compensation Details
Jaguar Health amends its annual report to include previously omitted information regarding directors, executive officers, and corporate governance.
NASDAQ
Jaguar Health's 10-K filing highlights progress in cancer therapy-related diarrhea treatment and commercial expansion with Gelclair, while addressing ongoing financial challenges and future strategies.
NASDAQ
Jaguar Health has filed an amendment to its annual report to include previously omitted information regarding directors, executive officers, and corporate governance.
NASDAQ
Jaguar Health's 10-K filing highlights the company's ongoing efforts in developing and commercializing plant-based pharmaceuticals for gastrointestinal issues in both humans and animals.